Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition
| Autor: | Andreas Austgulen Westin, Ingrid Castberg, Olav Spigset, Malin Brekke, Eirik Skogvoll, Espen Molden |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Olanzapine
Adult Perphenazine medicine.medical_specialty medicine.medical_treatment Pregnancy Trimester Third Pharmacology 030226 pharmacology & pharmacy Gastroenterology Drug Administration Schedule 03 medical and health sciences Young Adult 0302 clinical medicine Pregnancy Internal medicine Medicine Humans Pharmacology (medical) Ziprasidone Registries Antipsychotic Clozapine Retrospective Studies medicine.diagnostic_test business.industry Norway Research Articles medicine.disease Therapeutic drug monitoring Quetiapine Female Drug Monitoring business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Zdroj: | Clinical Pharmacology and Therapeutics |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | Although pregnancy is known to cause changes in drug pharmacokinetics, little is known about its impact on serum levels of antipsychotics. In this study we retrospectively assessed 201 routine serum antipsychotic therapeutic drug monitoring concentration measurements obtained from a total of 110 pregnancies in 103 women, and 512 measurements from the same women before and after pregnancy. Serum concentrations in the third trimester were significantly lower than baseline for quetiapine (−76%; confidence interval (CI), −83%, −66%; P < 0.001) and aripiprazole (−52%; CI, −62%, −39%; P < 0.001), but not for olanzapine (−9%; CI, −28%, +14%; P = 0.40). For the remaining antipsychotics (perphenazine, haloperidol, ziprasidone, risperidone, and clozapine), our dataset was limited, but it indicates that concentrations may decline at least for perphenazine and possibly also for haloperidol. Even though the clinical consequence of the serum concentrations decline remains to be elucidated, our results warrant close clinical monitoring throughout pregnancy, preferentially supported by therapeutic drug monitoring. © 2017 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text